Related by context. All words. (Click for frequent words.) 68 Thrombolysis 63 Oral Fingolimod 63 Myocardial Infarction Study 62 Multicenter Study 62 Treatment Outcome 62 NCIC Clinical Trials 62 Observational Study 62 Radiation Therapy Oncology 62 unfractionated heparin UFH 62 Severe Sepsis 61 Gastric Cancer 61 Randomized Evaluation 61 Renal Artery 61 Antiplatelet 61 Patient Outcomes 61 Patients Undergoing 60 oral antidiabetic medication 60 Ischemic Stroke 60 Platelet Inhibition 60 Acute Myocardial Infarction 60 Dialysis Outcomes 60 Hemodialysis Patients 60 Hematological 60 Val HeFT 60 Prospective Randomized 60 Acute Decompensated Heart Failure 60 Lung Injury 60 insulin glulisine 60 Group RTOG 60 Group NCIC CTG 60 Peripheral Arterial 59 Pivotal Trial 59 Multicentre 59 CHAMPION PCI 59 Acute Coronary Syndromes 59 Prolongs Survival 59 Eur J 59 Coronary Artery Bypass Graft 59 Suicide Grief Support 59 Prospective Multicenter 59 CLARITY TIMI 59 See WARNINGS 59 Clinical Trial Evaluating 59 Multiethnic Study 59 Randomized Study 59 Carotid Endarterectomy 59 Myocardial Ischemia 59 Phase Ib Clinical Trial 58 Heterozygous Familial Hypercholesterolemia 58 Related Disorders Support 58 Acute Coronary Syndromes ACS 58 Vistec Electron Beam Lithography 58 Clinical Outcome 58 Initiates Clinical Trial 58 Patients Treated With 58 Meta Analysis 58 J Clin 58 essential thrombocythemia ET 58 RE LY ® 58 Multicenter 58 Heart Failure Patients 58 Lymphocytic 58 Adjunctive 58 Infarct 58 Pivotal Clinical Trial 58 Surgeons Oncology 58 Diabetic Foot Ulcer 58 B Streptococcus GBS 58 Cardiac Resynchronization 58 Pooled Analysis 58 Renal Cancer 57 Blood Pressure Monitoring 57 DMDA Peer Support 57 ECASS 57 sunitinib Sutent 57 Heart Transplant Recipients 57 J Am Coll 57 #-# Full Text 57 Acute Stroke 57 Randomized Clinical Trials 57 ACTEMRA TM 57 Practice Patterns 57 Improves Outcomes 57 Breast Feeding Support 57 Nesiritide 57 See CLINICAL PHARMACOLOGY 57 ILLUSTRATE 57 Acute Liver Failure 57 stage IIIB 57 NATRECOR R 57 Reduces Mortality 57 Carotid Revascularization Endarterectomy vs. 57 metastatic malignant 57 GW# [003] 57 candesartan cilexetil 57 Ischemic 57 Trandolapril 57 multicenter randomized controlled 57 Hormone Refractory Prostate Cancer 57 fosbretabulin 57 Abciximab 57 Chronic Heart Failure 57 Controlled Trial 57 Carotid Stenting 57 Decompensated Heart Failure 57 ug dose 57 Elderly Patients 57 Cooperative Oncology 57 AIDS Clinical Trials 57 Cornea Donor Study 57 deep venous thromboses 57 Placebo Controlled Trial 57 Diabetic Patients 57 Insulin Therapy 56 ExTRACT TIMI 56 TO AVOID PREGNANCY WHILE 56 Study Evaluating 56 Non Alcoholic Steatohepatitis 56 FluCAM arm 56 NSABP B 56 Systolic Hypertension 56 NICE SUGAR 56 Castration Resistant Prostate Cancer 56 unstable angina UA 56 metastatic neuroendocrine tumors 56 Ozarelix 56 multicentre randomized double 56 Phase IIIb 56 Mycophenolate Mofetil 56 HCV RESPOND 2 56 Controlled Study 56 Improves Survival 56 Breast Carcinoma 56 Renal Impairment 56 prospective randomized multicenter 56 Neoadjuvant Chemotherapy 56 Meets Primary Endpoint 56 Venous Thromboembolism 56 Subgroup Analysis 56 IMiDs ® compound 56 SANTE 56 Systemic Sclerosis 56 ACE Inhibitors 56 Patients Receiving 56 Cardiac Resynchronization Therapy 56 stage IIIb IV 56 Thiazolidinediones 56 Soft Tissue Sarcoma 56 Demonstrates Sustained 56 dalteparin 56 #:#-# [024] 56 Adjuvant Treatment 56 B Streptococcus 56 q#h 56 Gynecologic Oncology Group 56 Combination REOLYSIN R 56 Inflammatory Markers 56 First Patient Enrolled 56 Atypical Hemolytic Uremic Syndrome 56 HYVET 55 Enzyme Replacement Therapy 55 receiving VELCADE 55 label multicenter 55 XIENCE V Stent System 55 Long Term Efficacy 55 Nonalcoholic Fatty Liver Disease 55 ENGAGE AF TIMI 55 EURIDIS 55 Acute MI 55 FDA APPROVES 55 Complicated Skin 55 surgically resected 55 HCV SPRINT 55 Randomized Trials 55 treatment naive genotype 55 8mg/kg 55 phase IIIb 55 number NCT# ClinicalTrials.gov 55 Tumor Response 55 Chronic Sinusitis 55 Non Invasive Treatment 55 Solid Tumours 55 treatment naïve genotype 55 Schizophrenia Treatment 55 Antiviral Therapy 55 dual endothelin receptor antagonist 55 Relapsed Refractory 55 Symptom Relief 55 receiving prophylactic anticoagulation 55 alfa 2a 55 Clinical Evaluation 55 Patients Treated 55 GOUT 55 Naive Patients 55 Obese Patients 55 Treated Patients 55 BARACLUDE ® 55 Laryngeal Cancer 55 ORENCIA ® 55 Feasibility Trial 55 Accelerated Partial Breast Irradiation 55 Completes Enrollment 55 TMC# C# 55 Aortic Valve Replacement 55 BR.# 55 Intracerebral Hemorrhage 55 Reduces Risk 55 Renal Cell Carcinoma RCC 55 Vertebral Fractures 55 Randomized Controlled 55 prospective nonrandomized 55 atypical Hemolytic Uremic Syndrome 55 Lung Cancer Trial 55 nicardipine 55 PERSEUS 55 Myelodysplastic Syndrome MDS 55 prospective multicentre 55 Invasive Breast Cancer 55 aplastic anemia AA 55 Liver Failure 55 nadroparin 55 Virologic 55 placebo controlled Phase III 55 ENESTnd 55 Thromboembolism 55 REALITY Trial 55 Combination Treatment 55 Arimidex Tamoxifen Alone 55 elevated transaminases 55 Cardiovascular Risk Factors 55 INCB# [003] 55 Endarterectomy 55 Randomized Controlled Trials 55 somatostatin analog 55 tenecteplase 55 Study Demonstrates 55 Shanxi Puda Coal 55 Pharmacokinetics PK 55 Shows Promise Against 54 VASCULAR 54 Prospective Cohort Study 54 conducted retrospective cohort 54 weekly subcutaneous injections 54 multicenter phase 54 mcg BID 54 epoetin alpha 54 Cancer Incidence Mortality 54 INTEGRILIN R 54 TAXUS ATLAS 54 Cholesterol Levels SPARCL 54 patients undergoing percutaneous 54 Thromboembolic 54 CIMZIA TM certolizumab pegol 54 biliary tract cancer 54 randomized multicenter 54 IN PATIENTS WITH 54 CARE HF 54 oxycodone CR 54 myelodysplastic myeloproliferative diseases 54 BCIRG 54 PEG IFN 54 Adjuvant Chemotherapy 54 Tri Isthmus 54 Hepatocellular Carcinoma 54 ST Segment Elevation 54 Autologous Stem Cell Transplantation 54 Prevent Stroke 54 Myocardial Infarction 54 Postmenopausal 54 STENT 54 underwent resection 54 Antihypertensive 54 Curr Opin 54 Percutaneous Coronary Intervention 54 Liver Metastases 54 myocardial infarction ventricular fibrillation 54 Thyroid Cancer Support 54 J Am Acad 54 Systemic Lupus Erythematosus SLE 54 Hypertriglyceridemia 54 Aggressive Reduction 54 #:# -# [004] 54 MEDNAX Pediatrix Medical 54 recurrent glioblastoma multiforme 54 prospective multicenter 54 plus COPEGUS 54 Phase IIIb study 54 Cutaneous T 54 Neurologic Disorders 54 Phase 2a Clinical Trial 54 Relapsed Multiple Myeloma 54 Newly Diagnosed Multiple Myeloma 54 Metastatic Prostate Cancer 54 refractory cutaneous T 54 HER2 Positive Breast Cancer 54 Betaferon R 54 papillary renal cell carcinoma 54 Earnings Preview Altria 54 Educational Bereavement Support 54 Genetic Markers 54 Investigational Treatment 54 antiretroviral naïve 54 COPERNICUS 54 MULTAQ 54 Metabolic Endocrinology 54 vinca alkaloid 54 Sleep Disordered Breathing 54 comparator arm 54 Septic Shock 54 Lowers Risk 54 tirofiban 54 RE LY 54 registrational Phase 54 Phase 2b Trial 54 Clinical Efficacy 54 Post Operative 54 lopinavir r arm 54 metastatic GIST 54 Intervention Trial 54 Abrupt discontinuation 54 Aberdeen GriefShare Support 54 prospective observational 54 Colorectal Cancer Study 54 Advanced Renal Cell 54 adversely affect LHC 54 Xelox 54 Left Ventricular Hypertrophy 54 moderate hepatic impairment 54 Paclitaxel Carboplatin 54 multicenter placebo controlled 53 MEND CABG 53 Chronic Pain Survivors 53 Interventional Procedures 53 Knee Osteoarthritis 53 Patient Registry 53 Screening Trial 53 Sleep Disturbances 53 Scandinavian Simvastatin Survival 53 Study ADCS 53 UA NSTEMI 53 multicenter prospective 53 failure ADHF 53 Prospective Randomized Trial 53 Prostate Cancer Treatment 53 AA Amyloidosis 53 Shows Efficacy 53 pain palliation 53 Rheumatoid Arthritis Patients 53 LEXIVA r 53 mild renal insufficiency 53 Cancer Patients Treated 53 Malignancies 53 Myeloma Patients 53 Pediatric Patients 53 Renal Insufficiency 53 Psychopharmacol 53 Fracture Risk 53 Increased Mortality 53 Venous Thrombosis 53 Peripheral Vascular Disease 53 Radiation Treatment 53 Heart Failure Trial 53 advanced hepatocellular carcinoma 53 CTAP# Capsules 53 Cardiovascular Outcomes 53 symptomatic carotid stenosis 53 fasting serum 53 patients undergoing CABG 53 Severe Asthma 53 Asymptomatic 53 unstable angina pectoris 53 Hematologic 53 Stent Placement 53 INSPIRE Trial Phase III 53 patientswith 53 Randomized Phase II 53 Bayer HealthCare Onyx Pharmaceuticals 53 Patients Suffering 53 mGluR5 negative 53 Diffuse Large B 53 Therapy Improves 53 Stable Angina 53 Levels Linked 53 undergoing coronary angiography 53 Randomized Phase 53 PROCRIT R 53 Juvenile Idiopathic Arthritis 53 abacavir Ziagen 53 APPRAISE 53 Denufosol 53 Myelodysplastic Syndrome 53 ARIXTRA 53 Valvular Heart Disease 53 4mg/kg 53 multicenter Phase II 53 Digital Mammographic Imaging 53 HOLDING LTD 53 Helps Predict 53 Evaluation WISE 53 Improved Survival 53 ATACAND 53 psoriatic arthritis PsA 53 metastatic gastric 53 Nilotinib 53 BZA CE 53 Treatment Resistant 53 Phase Ib II 53 #:#-#,# [003] 53 Myelofibrosis 53 bivalirudin alone 53 recurrent malignant glioma 53 ONCOLOGY 53 ß blockers 53 adalimumab Humira 53 ANN INTERN MED 53 Intervention Effectiveness 53 CCX# B 53 Robot Assisted 53 Drug Prevents 53 cisplatin vinorelbine 53 Who Underwent 53 Orthop Surg 53 Prognostic Significance 53 Myelodysplastic Syndromes 53 Glatiramer Acetate 53 PRoFESS 53 Node Positive 53 Marrow Transplant 53 Bone Marrow Transplants 53 GELA 53 heFH 53 NSTE ACS 53 PKC# 53 Antitumor Activity 53 prospective observational cohort 53 Earnings Preview Wendy Arby 53 plus dexamethasone 53 ulcerative colitis Crohn disease 53 Free Full Text 53 Minimally Invasive Treatment 53 Slows Progression 53 See Mantra Venture 53 Advanced Melanoma 53 Limb Salvage 53 Navelbine ® 53 humanized interleukin 6 53 J Nutr 53 ACUITY trial 53 Cystectomy 53 rt PA 53 Surgical Treatment 53 efaproxiral 53 fluvastatin 53 CALGB # [002] 53 Renal Replacement Therapy 53 Tiotropium 53 Intracranial Aneurysms 53 Edge STudy 53 Genes Predict 53 evaluating tivozanib 53 Jim Slosiarek SourceMedia 52 EGFR HER2 52 Lung Cancer Patients 52 AIR2 Trial 52 RE LY trial 52 completely resected 52 Test Detects 52 Renal Anemia 52 FULL PRESCRIBING INFORMATION 52 Ziprasidone 52 Clinical Antipsychotic Trials 52 Flu Cy 52 de novo kidney transplant 52 Hepatocellular Carcinoma HCC 52 flutamide 52 Purchasing Organizations GPOs 52 Main Outcome Measure 52 RECORD1 52 refractory chronic lymphocytic 52 irbesartan 52 LUX Lung 52 Treatment Approaches 52 t2cure GmbH 52 Serdolect ® 52 Interstitial Cystitis 52 portal vein thrombosis 52 Prognostic Value 52 Anticoagulation 52 Safinamide 52 Abstract Full Text 52 nilotinib Tasigna 52 Chronic Kidney 52 Trial PCPT 52 Combo Therapy 52 Heart Failure Therapy 52 underwent CABG 52 splenectomized 52 dimeglumine 52 Preclinical Study 52 acadesine 52 milrinone 52 Degarelix 52 Pirfenidone 52 ritonavir boosted 52 randomized #:#:# 52 Folfox 52 Subtypes 52 perioperatively 52 Overactive Bladder 52 Minimally Invasive Procedure 52 Therapy Reduces 52 HER2 Positive 52 TRA 2P 52 evaluating REVLIMID 52 Survival Benefit 52 Its Tubular Products 52 dopamine D2 52 Prophylactic Treatment 52 Computed Tomographic 52 Helicobacter pylori eradication 52 Postmenopausal Women 52 Molecular Epidemiology 52 LUMINATE 52 CALGB 52 Surgical Outcomes 52 Neoadjuvant 52 morphometric vertebral fractures 52 familial amyloidotic polyneuropathy FAP 52 ISTODAX ® 52 CALERIE 52 Lipid Lowering Treatment 52 relapsing remitting MS RRMS 52 metastatic pancreatic 52 Lenalidomide 52 Ventricular Tachycardia 52 Genetic Epidemiology 52 Pharmacologic 52 Lung Cancer Survival 52 Osteoporosis Treatment 52 Neuroepidemiology 52 undergoing androgen deprivation 52 Renal Function 52 REVIVE Diabetes 52 PROactive 52 Shahid Bakeri Industries 52 icatibant 52 BRIM2 52 multicentre randomized 52 controlled multicenter 52 mg BID dose 52 multicenter randomized Phase III 52 pT2 52 VIIBRYD 52 Stress Incontinence 52 VADT 52 ancrod 52 Clostridium difficile Infection 52 randomized Phase III 52 receptor tyrosine kinase inhibitor 52 SOMERS NY Pepsi Bottling 52 Platinol ® cisplatin 52 phase IIb trial 52 Vascular Disease 52 Obstet Gynecol 52 Double Blind Randomized 52 sacral nerve stimulation 52 Intervention Effectiveness CATIE 52 hemodialysis patients 52 Treatment Reduces 52 SORT OUT III 52 Renal Failure 52 ULORIC 52 Hospitalized Patients 52 intravenous methylnaltrexone 52 achieved ACR# 52 observational cohort study 52 Aortic Dissection 52 liver transplant recipients 52 ADONIS 52 TG MV 52 relapsed MM 52 RLAI 52 Statistically Significant 52 suppl #S 52 blind multicenter 52 randomized Phase IIb 52 Anxiety Depression 52 EchoCRT 52 symptomatic BPH 52 Bivalirudin 52 Azopharma Product Development 52 brivaracetam 52 segment Accredo Health 52 docetaxel Taxotere ® 52 EOX 52 EVEREST II 52 Cloretazine 52 interferon gamma 1b 52 Reduced Risk 52 Androgen Deprivation Therapy 52 gefitinib Iressa 52 wholly owned immunotherapeutics 52 plus prednisone 52 Bronchiectasis 52 Bone Metastases 52 Kidney Transplant Patients 52 multicenter randomized 52 percutaneous transluminal coronary angioplasty 52 Motesanib 52 Peripheral Arterial Disease 52 nucleoside naive 52 ATRIA 52 Sipuleucel T 52 STRIDE PD 52 BARI 2D 52 Pharmacodynamic 52 immunomodulatory therapy 52 atazanavir ritonavir 51 BIOPHARMA 51 Follicular Lymphoma 51 PAUL Minn.MN 51 Guidelines Recommend 51 Hyperparathyroidism 51 BCG refractory 51 Hormone Receptor Positive 51 double blinded randomized 51 Coronary Artery Bypass Surgery 51 Clinical Trial Data 51 histologically confirmed 51 Cervical Dysplasia 51 CARDIOVASCULAR 51 Renal Cell Carcinoma 51 systolic hypertension 51 randomized Phase 2b 51 ACRIN 51 Ixempra 51 plus methotrexate 51 Alzheimer Disease Cooperative 51 Vertebral Fracture 51 Bipolar Depression 51 CLARITY study 51 GAMMAGARD 51 Racial Differences 51 colorectal carcinoma 51 Hematopoietic Stem Cell Transplantation 51 multicenter multinational 51 RECIST Response Evaluation Criteria 51 Afib 51 randomized blinded placebo 51 IIa Clinical Trial 51 M.D. Ph.D. 51 IL# PE#QQR 51 systemic hypotension 51 erlotinib Tarceva ® 51 tenofovir emtricitabine 51 Nebulized 51 APTIVUS R 51 cardiovascular calcification 51 bile acid sequestrant 51 TRO# 51 antibody MAb 51 certolizumab 51 Stereotactic Body Radiation Therapy 51 STRATEGY FOR AN OPEN 51 Prostate Cancer Patients 51 Reduces Pain 51 5q MDS 51 Telmisartan 51 LHRH receptor positive 51 Thal Dex 51 CYPHER Stent 51 PARTNER Trial 51 Psoriasis Area 51 #:#-#,# CrossRef Medline [002] 51 Improve Survival 51 ERGO Insurance 51 MGd 51 double blinded placebo 51 relapsed refractory multiple myeloma 51 eritoran 51 interferon ribavirin 51 COMPLETES ACQUISITION OF 51 LymphoStat B belimumab 51 labetalol 51 Chronic Constipation 51 Appears Safe 51 Solid Tumors 51 Small Bowel 51 multicentre study 51 Beta Blocker 51 Subgroup analysis 51 Guidelines Issued 51 Certolizumab pegol 51 Insulin Sensitivity 51 Asthma Intervention 51 Enzastaurin 51 Streptococci 51 multicentre 51 #mg/day [001] 51 multicenter randomized placebo controlled 51 Sorafenib HCC Assessment 51 Coronary Artery Calcium 51 Uterine Fibroids 51 Hepatitis C Treatment 51 Menopausal Symptoms 51 Treating Chronic 51 tachyarrhythmias 51 generalized edema 51 estramustine 51 CHARISMA trial 51 PATIENTS WITH 51 prospective randomized placebo 51 Novel Treatments 51 cisplatin gemcitabine 51 Sustained Efficacy 51 recurrent metastatic 51 TAXUS V 51 CLL SLL 51 neoadjuvant treatment 51 Prostate Cancer Clinical Trial 51 undergoing peritoneal dialysis 51 International Prognostic Scoring 51 Ovarian Cancer Patients 51 Related Mortality 51 venlafaxine Effexor 51 Poorly Controlled 51 Phase III randomized 51 phase IIb clinical 51 Sustained Reduction 51 Resistant Hypertension 51 Cloretazine ® 51 Therapy Shows Promise 51 Tyco Electronics Printed Circuit 51 undergoing radical cystectomy 51 R entecavir 51 Cognitive Impairment 51 Anticoagulants 51 advanced metastatic renal 51 Angioedema 51 MULTIPLE MYELOMA 51 Gosline Insurance 51 electrocardiography ECG 51 Megabank Mizuho Financial 51 dabigatran etexilate 51 FOLFOX4 51 Osteoporosis Drug 51 Investigator Initiated 51 de novo AML 51 Arch Intern Med 51 #mg BID [001] 51 multicentric 51 anti arrhythmic drug 51 Peginterferon 51 Lymphoma Patients 51 AEGR 51 overactive bladder syndrome 51 THERAPY FOR 51 JEFF LARSON MediaNews 51 CC genotype 51 Meta analyzes 51 advanced unresectable 51 Effectively Treats 51 Acute coronary syndromes 51 pan HDAC inhibitor 51 LAB CGRP 51 Premenopausal Women 51 Multicenter AIDS 51 INTERMAP 51 lorvotuzumab mertansine 50 gemcitabine carboplatin 50 Prognostic Factors 50 CRp 50 Postmenopausal hormone therapy 50 cathepsin K inhibitor 50 Slow Progression 50 HMG CoA reductase inhibitors 50 trials RCTs 50 cell lymphoma CTCL 50 Potentially Fatal 50 darunavir r 50 tumor histology 50 J Child Adolesc 50 Study Indicates 50 thrombocytopenic 50 aldosterone antagonists 50 transrectal ultrasound guided 50 Ejection Fraction 50 abstr 50 Chronic Myelogenous Leukemia 50 Dermatol 50 Osteoporosis Drugs 50 Epratuzumab 50 AUDIO PROVIDED BY 50 undergone radical prostatectomy 50 Critical Limb Ischemia 50 Statin Drugs 50 Hip Fractures 50 Platinol ® 50 Echocardiographic 50 Attack Trial ALLHAT 50 Contact Dermatitis 50 CIRCOR Aerospace Products 50 Hip Fracture 50 Multicenter Randomized 50 IFN alfa 50 Vasogen Celacade 50 Eye Diseases 50 Statin Therapy 50 receiving XGEVA 50 Drug Shows Promise 50 citalopram Celexa 50 5RTI 50 COPAXONE R 50 Chronic Lymphocytic Leukemia 50 FIRMAGON 50 Randomised Study 50 Common Toxicity Criteria 50 Tanespimycin 50 Mortality Risk 50 TURNS Treatment 50 REYATAZ r 50 Neupro R 50 COREG 50 paclitaxel poliglumex 50 cystoid macular edema 50 Nonsurgical 50 Increased Risk 50 Afatinib 50 Genasense ® 50 headache abdominal pain 50 Colitis Support 50 Beta Blockers 50 Arch Neurol 50 intermittent dosing 50 forodesine 50 TeleFutura Television 50 Catheter Ablation 50 CrossRef Medline 50 Peg IFN 50 symptomatic VTE 50 Copegus ribavirin 50 Benign Prostatic Hyperplasia 50 longitudinal cohort study 50 underwent surgical resection 50 Breast Tumor 50 ARCALYST ® rilonacept 50 abacavir lamivudine 50 active comparator 50 Kidney Function 50 B streptococcus 50 docetaxel Taxotere R 50 tapentadol ER 50 mg kg Hematide 50 PROSTVAC ® 50 PRESEPT 50 assessing T DM1 50 sorafenib Nexavar 50 Multicenter Phase 50 Aflibercept 50 ECOG PS 50 Phase IIIb clinical 50 Recurrent Breast Cancer 50 demonstrated antitumor activity 50 substudy 50 Lancet Oncol 50 Stem Cell Treatment 50 multicenter randomized clinical 50 mTOR mammalian target 50 Proves Effective 50 Clinical Practice Guidelines 50 glycoprotein IIb IIIa inhibitors 50 J Pediatr 50 Depressive Symptoms 50 ZOLINZA 50 Biol Phys 50 Helps Diagnose 50 phase IIb study 50 Randomised 50 Breast Cancer Recurrence 50 Study HERS 50 atherogenic dyslipidemia 50 CRQ 50 ABCB1 50 antiarrhythmic drug 50 Cognitive Problems 50 clinically evaluable 50 Arch Otolaryngol Head 50 rALLy clinical trial 50 galiximab 50 multicentre prospective 50 THERAPEUTICS INC. 50 Limited Transax 50 coronary revascularisation 50 NATRECOR ® 50 Shown Effective 50 Psychiatric Epidemiology 50 dyslipidaemia 50 An Opportunity Awaits 50 Mitomycin C 50 Treatment Naive Patients 50 Mesothelioma Treatment 50 anticlotting drugs 50 coronary revascularization 50 detrusor overactivity 50 Targeted Molecular Diagnostics 50 IL#B 50 μg dose 50 mu opioid agonist analgesics 50 MAGE A3 ASCI 50 CORP. ANNOUNCES 50 F FDG PET 50 TRITON TIMI 50 Dasatinib 50 Hyperkalemia 50 www.luxottica.com 50 Postoperative Pain 50 label Lipofen R 50 pegylated interferon alfa 2b 50 Systems Trelleborg Automotive 50 Asthma Treatment 50 LOUISMO 50 hemodialysis peritoneal dialysis 50 PFO migraine 50 recurrent sinusitis 50 Alpha Tocopherol Beta Carotene 50 Phase 1a clinical 50 haematologic 50 Radiation Induced 50 NDQ 50 Myelodysplastic Syndromes MDS 50 AMCG DEST FISH HUDV 50 Disease Progression 50 chromosome #p# [002] 50 Newly Diagnosed Patients 50 Amrubicin 50 Node Negative 50 Pelvic Organ Prolapse 50 Metastatic Pancreatic Cancer 50 Stent Implantation 50 BCR ABL inhibitor 50 3 Fatty Acids 50 histone deacetylase HDAC inhibitor 50 Respiratory Symptoms 50 chemoradiation therapy 50 MAM Utility Services 50 Purchasing Organizations 50 Evaluable 50 ONTARGET 50 Brain Shrinkage 50 saline placebo 49 Lung Cancers 49 Dialysis Patients 49 Cardiovascular Risk Reduction 49 Osteoarthritis Patients 49 Estrogen Receptor 49 HIV HCV coinfected 49 ABCSG 49 Tesmilifene 49 WorldHeart Announces 49 Treatment Algorithm 49 GHIS 49 ICD CRT 49 thalidomide Thalomid 49 Often Misdiagnosed 49 EF Precision 49 venous thromboembolic disease 49 HBeAg negative 49 Bowel Project NSABP 49 CAPRIE 49 Infected Patients 49 recurrent GBM 49 HCV Genotype 49 J Clin Oncol 49 DEB# 49 Interpersonal Psychotherapy 49 Functional Outcomes 49 controlled dose escalation 49 macrovascular disease 49 antiplatelet medications 49 Brain Stimulation 49 Chronic Hepatitis B 49 Breast Density 49 IV NSCLC 49 Highwinds Network 49 Adefovir 49 Am J Clin 49 metastatic colorectal 49 Osteoporotic Fractures 49 cytogenetic response 49 rituximab refractory 49 oral Hycamtin 49 VITAL Trial 49 #:#-#,# [002] 49 Teriflunomide 49 Breast Cancer Stem Cells 49 Hepatotoxicity 49 NCT# ClinicalTrials.gov 49 Esophageal 49 Recurrent Ovarian Cancer